Joaquín Martínez‐López

Research interests

Publications

• International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

  Journal of Clinical Oncology · 2025 · https://doi.org/10.1200/jco-24-01893

• Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.01008

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303379

• Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02528-9

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03175

• Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00592-4

• The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression

  Cancers · 2021 · 10.3390/cancers13020217

• Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

  Nature Medicine · 2021 · https://doi.org/10.1038/s41591-021-01622-0

• Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2116596

• Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

  Blood · 2020 · https://doi.org/10.1182/blood.2020008150

• IL-6–based mortality risk model for hospitalized patients with COVID-19

  Journal of Allergy and Clinical Immunology · 2020 · 10.1016/j.jaci.2020.07.009

• Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

  medRxiv · 2020 · 10.1101/2020.07.31.20165647

• Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study

  Journal of Hematology & Oncology · 2020 · 10.1186/s13045-020-00970-7

• Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01231

• Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30192-x

• Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.29

• Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.69.2517

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · https://doi.org/10.1182/blood-2014-01-550020

• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70380-2

• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

  Blood · 2012 · https://doi.org/10.1182/blood-2012-02-408922

• High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

  Blood · 2011 · https://doi.org/10.1182/blood-2011-07-370460

• Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

  Blood · 2011 · 10.1182/blood-2011-01-332320

• Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.33.1967

• Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70187-x

• Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.17.9721

• Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.

  PubMed · 2005

• Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts

  American Journal of Physiology-Heart and Circulatory Physiology · 1994 · 10.1152/ajpheart.1994.267.2.h844

Current projects

No projects listed.